• Azcoitia I., Sierra A. and Garcia-Segura L. M. (1999) Neuroprotective effects of estradiol in the adult rat hippocampus: interaction with insulin-like growth factor-I signalling. J. Neurosci. Res. 58, 815822.DOI: 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R
  • Chan G. C. K., Hinds T. R., Impey S. and Storm D. R. (1998) Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J. Neurosci. 18, 53225332.
  • Downer E., Boland B., Fogarty M. and Campbell V. (2001) Δ9-Tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptor. Neuroreport 12, 39733978.
  • Felder C., Joyce K. E., Briley E. M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A. L. and Mitchell R. L. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48, 443450.
  • Galve-Roperh I., Sánchez C., Cortés M. L., Gómez del Pulgar T., Izquierdo M. and Guzmán M. (2000) Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6, 313319.
  • Grundy R. I., Rabuffetti M. and Beltramo M. (2001) Cannabinoids and neuroprotection. Mol. Neurobiol. 24, 2952.
  • Hansen H. S., Moesgaard B., Hansen H. H., Schousboe A. and Petersen G. (1999) Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Lipids 34, S327S330.
  • Hansen H. H., Ikonomidou C., Bittigau P., Hansen S. H. and Hansen H. S. (2001a) Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal cell death. J. Neurochem. 76, 3946.DOI: 10.1046/j.1471-4159.2001.00006.x
  • Hansen H. H., Schmid P. C., Bittigau P., Lastres-Becker I., Berrendero F., Manzanares J., Ikonomidou C., Schmid H. H. O., Fernández-Ruiz J. J. and Hansen H. S. (2001b) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 14151427.DOI: 10.1046/j.1471-4159.2001.00542.x
  • Ikonomidou C., Mosinger J. L., Salles K. S., Labruyere J. and Olney J. W. (1989) Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J. Neurosci. 9, 28092818.
  • Maccarrone M., Lorenzon T., Bari M., Melino G. and Finazzi-Agro A. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275, 3193831945.
  • Mechoulam R., Panikashvili A. and Shohami E. (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8, 5861.
  • Mukhopadhyay S., Moore D., Ndengele M., Zahm D. S., Kearn C. S., Hillard C. J., Lechner A. J. and Howlett A. C. (2000) LPS-induced upregulation of CB2 cannabinoid receptors in rat brain microglia and murine macrophage RAW 264.7 cells. Proceedings of the ICRS symposium on the Cannabinoids, pp. 57. International Cannabinoid Research Society, Burlington.
  • Muthian S. and Hillard C. J. (2000) CB1 receptor antagonists are neuroprotective in focal cerebral ischemia-reperfusion injury. Proceedings of the ICRS symposium on the Cannabinoids, pp. 107. International Cannabinoid Research Society, Burlington.
  • Nagayama T., Sinor A. D., Simon R. P., Chen J., Graham S. H., Jin K. L. and Greenberg D. A. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 29872995.
  • Panikashvili D., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R. and Shohami E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527531.DOI: 10.1038/35097089
  • Pertwee R. G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129180.
  • Piomelli D., Giuffrida A., Calignano A. and Rodriguez de Fonseca F. (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21, 218224.
  • Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G. and Caput D. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240244.
  • Sarker K. P., Obara S., Nakata M., Kitajima I. and Maruyama I. (2000) Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 472, 139144.
  • Schlicker E. and Kathmann M. (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565572.
  • Sherwood N. M. and Timiras P. S. (1970) A Stereotaxic Atlas of the Developing Rat Brain. University of California Press, Los Angeles, CA, USA.
  • Sim-Selley L. J., Brunk L. K. and Selley D. E. (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414, 135143.
  • Van der Stelt M., Veldhuis W. B., Bär P. R., Veldink G. A., Vliegenthart J. F. G. and Nicolay K. (2001a) Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21, 64756479.
  • Van der Stelt M., Veldhuis W. B., Van Haaften G. W., Fezza F., Bisogno T., Bär P. R., Veldink G. A., Vliegenthart J. F. G., Di Marzo V. and Nicolay K. (2001b) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 87658771.
  • Wilson R. I. and Nicoll R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588592.DOI: 10.1038/35069076